Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue

In the pivotal phase 3 efficacy trial (NCT02747927) of the TAK-003 dengue vaccine, 5 of 13,380 TAK-003 recipients and 13 of 6,687 placebo recipients experienced two episodes of symptomatic dengue between the first dose and the end of the study, ∼57 months later (patients received the second dose 3 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Sáez-Llorens, Xavier, Biswal, Shibadas, Borja-Tabora, Charissa, Fernando, LakKumar, Liu, Mengya, Wallace, Derek, Folschweiller, Nicolas, Reynales, Humberto, LeFevre, Inge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077010/
https://www.ncbi.nlm.nih.gov/pubmed/36878213
http://dx.doi.org/10.4269/ajtmh.22-0673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077010/
https://www.ncbi.nlm.nih.gov/pubmed/36878213
http://dx.doi.org/10.4269/ajtmh.22-0673

Ejemplares similares